UnknownPhase 1NCT02200718
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Studying Pediatric multiple sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immune Response BioPharma, Inc.
- Principal Investigator
- Richard M Bartholomew, Ph.DImmune Response BioPharma, Inc.
- Intervention
- NeuroVax(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2020 – 2024
Study locations (1)
- CRO, San Diego, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02200718 on ClinicalTrials.govOther trials for Pediatric multiple sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07571304Dual-Task Training in Pediatric Multiple SclerosisIstanbul University - Cerrahpasa
- ACTIVE NOT RECRUITINGNCT04593082Obesity and Pediatric Multiple SclerosisUniversity of Virginia
- ACTIVE NOT RECRUITINGNANCT04782466ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research ProgramThe Hospital for Sick Children
- ACTIVE NOT RECRUITINGPHASE3NCT01892722Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisNovartis Pharmaceuticals